Brise, AbbVie Update Migraine Drug License Deal
Brise Pharmaceuticals provided an update on its license agreement with AbbVie covering two preclinical migraine programs.
Updated on Nov. 2, 2026 in Biotech
Brise Pharmaceuticals announced an update on its exclusive license agreement with AbbVie, under which AbbVie will lead global development and commercialization of two Brise preclinical migraine programs. The aggregated potential transaction value could reach up to US $757 million plus royalties on future sales.
Why it matters
The deal places Brise's migraine research under the development and commercial reach of a major pharmaceutical company, extending its work beyond discovery. Brise has also achieved several near-term milestones, signaling progress on its pipeline as of the announcement.
The up-to-$757 million figure is a maximum aggregated potential value that includes development, commercial, regulatory and sales milestones plus royalties, rather than a guaranteed payment. The breakdown of payments across those milestones and their timing has not been disclosed.
The players
Brise Pharmaceuticals
A Shanghai-based biotechnology company founded in June 2021 that conducts discovery work on migraine therapies and has an oral small-molecule candidate, BR005, in pivotal clinical trials.
AbbVie
A global biopharmaceutical company that markets a broad range of prescription medicines and is leading global development and commercialization of the two Brise migraine programs.
The details
Under the collaboration, Brise is responsible for discovery efforts, while AbbVie leads global development and commercialization for two preclinical migraine programs. Brise's own pipeline includes BR005, an oral small-molecule drug in pivotal clinical trials for acute treatment of migraine in adults.
Timeline
2024: Brise and AbbVie entered the exclusive license agreement.
June 2021: Brise Pharmaceuticals was founded in Shanghai, China.
November 2, 2026: Brise announced the update on the AbbVie agreement.
The Tech Race
Brise's BR005 is an oral small-molecule candidate in pivotal trials for acute migraine treatment in adults, placing the company among developers pursuing non-injectable acute migraine options. Pairing that pipeline with AbbVie's global commercial reach positions Brise to compete on the same therapeutic front as other migraine developers.
For patients who experience migraines, a successful pivotal trial for an oral acute treatment could eventually add a new option to existing therapies. Any product from these programs would still need regulatory review before it becomes available to consumers.
The takeaway
Partnerships that pair a developer's discovery work with a large company's global commercial reach can speed a drug toward patients. Readers following migraine treatment can watch whether BR005 advances through its pivotal trials.
Further reading
Explore more developments in Biotech to see how partnerships like this one are shaping drug development.
More information
Review the current Brise Pharmaceuticals pipeline information on the company's official website.
